TuesdayMar 18, 2025 9:00 am

D-Wave Quantum Inc. (NYSE: QBTS) Demonstrates Quantum Supremacy on a Real-World Problem

D-Wave has shown quantum computational supremacy on a useful, real-world problem, a first in the industry, highlighting the potential of quantum computing for materials discovery and complex simulations beyond classical computational limits. A peer-reviewed paper published in Science validates that D-Wave’s annealing quantum computer solved a magnetic materials simulation problem that is beyond the capabilities of classical supercomputers. The simulation, which took minutes to solve on D-Wave’s system, would require nearly one million years and more electricity than the world’s annual consumption on a GPU-based supercomputer. The Advantage2 annealing quantum computer prototype was used to achieve this milestone and is…

Continue Reading

FridayMar 07, 2025 10:45 am

D-Wave Quantum Inc. (NYSE: QBTS), Staque Develop Hybrid Quantum Application to Optimize Autonomous Agriculture Vehicles

The companies expect the application to accelerate autonomy in agriculture, streamlining agricultural operations. The technology aims to enhance efficiency in large-scale farming by providing real-time optimization solutions. The initiative is part of a broader strategic partnership between D-Wave and Staque to accelerate commercial adoption of annealing quantum computing. D-Wave Quantum Inc. (NYSE: QBTS) (“D-Wave”), a leader in quantum computing systems, software, and services, and the first supplier of production-grade quantum computers, and Staque, a leading consulting and development practice in AI, blockchain and quantum computing, collaborated to develop a hybrid-quantum system designed to optimize the movements of autonomous agricultural vehicles…

Continue Reading

WednesdayMar 05, 2025 11:30 am

Calidi Biotherapeutics Inc. (NYSE American: CLDI) Pioneers Systemic Virotherapy with RTNova Platform

Calidi’s RTNova platform leverages engineered enveloped vaccinia viruses designed for systemic delivery. Calidi’s groundbreaking virotherapy holds “immense promise in revolutionizing the treatment landscape for cancer patients with advanced solid tumors,” says CEO. Calidi Biotherapeutics (NYSE American: CLDI) is a clinical-stage biotechnology company at the forefront of developing innovative immunotherapies for cancer treatment. Most recently, the company has captured the spotlight for the development of its proprietary systemic platform, RTNova (https://ibn.fm/Z4pM3). The platform represents a significant advancement in systemic virotherapy, particularly in the utilization of enveloped virotherapies to target metastatic tumors across the body. Antitumor virotherapy employs viruses that selectively infect and…

Continue Reading

Contact us: (512) 354-7000